다계통 위축증(MSA) 환자수 분석 및 예측(2026-2035년)

Multiple System Atrophy (MSA) is a rare, progressive neurodegenerative disorder characterized by autonomic dysfunction, parkinsonism, cerebellar ataxia, and severe motor impairment. The disease is classified as an alpha-synucleinopathy due to the abnormal accumulation of alpha-synuclein protein within the central nervous system. MSA is generally categorized into two major clinical subtypes: Multiple System Atrophy-Parkinsonian (MSA-P) and Multiple System Atrophy-Cerebellar (MSA-C). The condition progresses rapidly and is associated with substantial disability, reduced quality of life, and increased healthcare utilization.

Patient population analysis plays a critical role in understanding disease prevalence, incidence, diagnosed patient pools, demographic distribution, disease progression patterns, mortality rates, and treatment eligibility. Such analyses support pharmaceutical companies, healthcare providers, research institutions, and policymakers in strategic planning, clinical trial recruitment, market forecasting, and healthcare resource allocation. As emerging therapies advance through clinical development and rare disease research receives increasing attention, the demand for comprehensive MSA patient population analysis is expected to expand significantly throughout the forecast period.

Market Drivers

Growing Awareness of Rare Neurological Disorders

One of the primary factors driving the market is increasing awareness of rare neurodegenerative diseases among healthcare professionals, researchers, and patient advocacy organizations. Educational initiatives and physician training programs are improving disease recognition and supporting earlier diagnosis.

Enhanced awareness is contributing to the identification of previously undiagnosed patients, thereby improving the accuracy of patient population estimates and epidemiological assessments.

Improvements in Diagnostic Technologies

Advancements in neuroimaging, autonomic testing, neurological assessments, and biomarker research are improving diagnostic accuracy for MSA. Historically, MSA was frequently misdiagnosed due to symptom overlap with Parkinson's disease and other movement disorders.

Improved diagnostic capabilities are increasing the number of accurately identified patients and strengthening the quality of patient population data used for research and market planning.

Expanding Orphan Drug Development Activity

Growing pharmaceutical investment in MSA therapeutic development is creating greater demand for patient population analytics. Companies developing orphan drugs require detailed epidemiological information to assess market opportunities, estimate addressable patient populations, and support regulatory submissions.

As more investigational therapies enter clinical development, patient population analysis becomes increasingly important for commercial planning and clinical trial execution.

Increasing Use of Real-World Evidence

Healthcare organizations are increasingly utilizing electronic health records, disease registries, insurance databases, and real-world evidence platforms to better understand rare disease populations.

The availability of large-scale healthcare datasets is enabling more comprehensive analysis of patient demographics, disease progression, treatment patterns, and healthcare utilization, supporting market growth.

Market Restraints

Limited Availability of Patient Data

Because MSA is a rare disease, patient populations remain relatively small compared to other neurological disorders. The limited number of diagnosed cases can restrict the availability of robust epidemiological data and affect the accuracy of population estimates.

Small sample sizes may also create challenges when conducting large-scale population studies.

Diagnostic Challenges and Misclassification

MSA shares clinical characteristics with Parkinson's disease, progressive supranuclear palsy, and other neurodegenerative disorders. Diagnostic overlap may result in delayed diagnosis or disease misclassification.

These challenges can affect epidemiological assessments and complicate efforts to accurately quantify patient populations.

Variability in Healthcare Reporting Systems

Differences in healthcare infrastructure, diagnostic practices, disease registries, and reporting standards across countries may create inconsistencies in patient population data.

Limited surveillance capabilities in certain regions can further affect the completeness of global epidemiological analyses.

Technology and Segment Insights

The global multiple system atrophy patient population analysis market can be segmented by disease subtype, patient category, data source, application, end user, and geography.

By disease subtype, the market includes MSA-P and MSA-C. MSA-P accounts for a substantial proportion of diagnosed cases in many regions and is often associated with clinical features resembling Parkinson's disease. MSA-C remains particularly prevalent in certain geographic populations and contributes significantly to overall disease burden.

By patient category, the market includes diagnosed prevalent cases, diagnosed incident cases, treated patients, untreated patients, and therapy-eligible patient populations. Diagnosed prevalent cases represent a major segment because they form the foundation for healthcare planning, market assessment, and treatment forecasting.

By data source, the market includes hospital databases, electronic health records, disease registries, insurance claims databases, academic research studies, government healthcare databases, and real-world evidence platforms. Electronic health records and disease registries are increasingly important due to their ability to provide longitudinal patient insights and support large-scale epidemiological research.

By application, the market encompasses prevalence analysis, incidence analysis, mortality assessment, patient segmentation, disease burden evaluation, clinical trial feasibility studies, treatment eligibility assessment, and forecasting models. Prevalence and incidence analyses remain central applications because they support healthcare policy development and commercial strategy planning.

By end user, the market serves pharmaceutical companies, biotechnology firms, healthcare providers, academic institutions, contract research organizations, government agencies, and healthcare consulting firms. Pharmaceutical and biotechnology companies account for a significant share due to their growing involvement in orphan drug development and market opportunity assessment.

Technological advancements are transforming patient population analysis through artificial intelligence, machine learning, predictive analytics, genomic research, and advanced healthcare data management platforms. These technologies improve patient identification, disease forecasting, data integration, and epidemiological modeling. The integration of digital health tools and real-world evidence platforms is also enhancing the accuracy and reliability of patient population assessments.

Geographically, North America holds a significant share of the market due to advanced healthcare infrastructure, strong rare disease research activity, extensive patient databases, and favorable regulatory support for orphan diseases. Europe remains a major market supported by robust healthcare systems, disease registries, and collaborative neurological research networks. Asia-Pacific is expected to witness substantial growth owing to improving healthcare infrastructure, increasing awareness of neurological disorders, expanding diagnostic capabilities, and growing investment in rare disease research. Latin America and the Middle East & Africa are also gradually strengthening their epidemiological research capabilities and healthcare data collection systems.

Competitive and Strategic Outlook

The multiple system atrophy patient population analysis market is characterized by increasing collaboration among pharmaceutical companies, academic institutions, healthcare organizations, patient advocacy groups, and research agencies. Stakeholders are investing in advanced analytics platforms, rare disease registries, epidemiological databases, and real-world evidence programs to improve patient identification and disease understanding.

Strategic initiatives increasingly focus on expanding patient registries, enhancing data quality, improving diagnostic pathways, and supporting global epidemiological studies. Companies developing MSA therapies are utilizing patient population analyses to optimize clinical trial recruitment, estimate market potential, and support commercialization strategies.

As therapeutic pipelines continue to expand and healthcare systems prioritize rare disease management, demand for comprehensive patient population intelligence is expected to increase substantially.

Conclusion

The global multiple system atrophy patient population analysis market is poised for sustained growth through 2031, supported by increasing awareness of rare neurodegenerative diseases, advances in diagnostic technologies, expanding healthcare data availability, and growing orphan drug development activity. Accurate patient population analysis is essential for epidemiological research, clinical trial planning, healthcare resource allocation, and commercial decision-making. Although challenges related to limited patient numbers, diagnostic complexity, and data variability remain, continued advancements in healthcare analytics, real-world evidence generation, and rare disease research are expected to strengthen market growth and improve understanding of the global MSA patient population.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 Key Findings
• 1.3 Patient Population Overview
• 1.4 Epidemiology Highlights
• 1.5 Key Regional Insights
• 1.6 Key Country Insights
• 1.7 Forecast Highlights (2025-2045)
• 1.8 Future Outlook

2. Disease Overview

• 2.1 Introduction to Multiple System Atrophy (MSA)
• 2.2 Disease Background and History
• 2.3 Disease Classification
  • 2.3.1 Multiple System Atrophy-Parkinsonian Type (MSA-P)
  • 2.3.2 Multiple System Atrophy-Cerebellar Type (MSA-C)
• 2.4 Disease Pathophysiology
• 2.5 Risk Factors and Disease Progression
• 2.6 Clinical Manifestations
• 2.7 Disease Burden Assessment
• 2.8 Diagnostic Pathway Analysis
• 2.9 Challenges in Diagnosis
• 2.10 Unmet Clinical Needs

3. Patient Population Overview

• 3.1 Global Patient Population Analysis
• 3.2 Historical Epidemiology Assessment (2021-2024)
• 3.3 Forecast Methodology (2025-2045)
• 3.4 Epidemiology Assumptions and Modelling Framework
• 3.5 Diagnosed vs Undiagnosed Population Assessment
• 3.6 Disease Awareness Impact Analysis
• 3.7 Healthcare Access Impact Analysis
• 3.8 Future Patient Population Trends

4. Epidemiology Analysis

• 4.1 Global Epidemiology Overview
  • 4.1.1 Total Prevalent Cases
  • 4.1.2 Total Incident Cases
  • 4.1.3 Diagnosed Prevalent Cases
  • 4.1.4 Diagnosed Incident Cases
  • 4.1.5 Disease Type Distribution
  • 4.1.6 Age-Specific Epidemiology
  • 4.1.7 Gender-Specific Epidemiology
  • 4.1.8 Disease Severity Distribution
  • 4.1.9 Forecast Analysis (2025-2045)
• 4.2 By Disease Type
  • 4.2.1 MSA-P Epidemiology
  • 4.2.2 MSA-C Epidemiology
  • 4.2.3 Mixed Phenotype Distribution
• 4.3 By Gender
  • 4.3.1 Male Population Analysis
  • 4.3.2 Female Population Analysis
• 4.4 By Age Group
  • 4.4.1 Below 40 Years
  • 4.4.2 40-49 Years
  • 4.4.3 50-59 Years
  • 4.4.4 60-69 Years
  • 4.4.5 70 Years and Above
• 4.5 By Disease Severity
  • 4.5.1 Early Stage Population
  • 4.5.2 Moderate Stage Population
  • 4.5.3 Advanced Stage Population
• 4.6 By Diagnosis Status
  • 4.6.1 Diagnosed Cases
  • 4.6.2 Undiagnosed Cases
  • 4.6.3 Misdiagnosed Cases

5. Patient Population Segmentation Analysis

• 5.1 By Disease Type
  • 5.1.1 MSA-P
  • 5.1.2 MSA-C
  • 5.1.3 Mixed Phenotypes
• 5.2 By Gender
  • 5.2.1 Male
  • 5.2.2 Female
• 5.3 By Age Group
  • 5.3.1 Below 40 Years
  • 5.3.2 40-49 Years
  • 5.3.3 50-59 Years
  • 5.3.4 60-69 Years
  • 5.3.5 70 Years and Above
• 5.4 By Disease Severity
  • 5.4.1 Early Stage
  • 5.4.2 Moderate Stage
  • 5.4.3 Advanced Stage
• 5.5 By Diagnosis Status
  • 5.5.1 Diagnosed Cases
  • 5.5.2 Undiagnosed Cases
  • 5.5.3 Misdiagnosed Cases

6. Disease Burden Analysis

• 6.1 Clinical Burden Assessment
• 6.2 Economic Burden Assessment
• 6.3 Mortality Analysis
• 6.4 Morbidity Analysis
• 6.5 Quality of Life Impact
• 6.6 Caregiver Burden Assessment
• 6.7 Healthcare Resource Utilisation
• 6.8 Future Disease Burden Trends

7. Diagnosis and Patient Journey Analysis

• 7.1 Symptom Onset Assessment
• 7.2 Time to Diagnosis Analysis
• 7.3 Referral Pathway Assessment
• 7.4 Differential Diagnosis Challenges
• 7.5 Diagnostic Delays Analysis
• 7.6 Patient Journey Mapping
• 7.7 Treatment Initiation Trends
• 7.8 Long-Term Disease Management Pathway

8. Geographical Analysis

• 8.1 North America
  • 8.1.1 Total Prevalence
  • 8.1.2 Total Incidence
  • 8.1.3 Diagnosed Cases
  • 8.1.4 Disease Type Distribution
  • 8.1.5 Age-Specific Epidemiology
  • 8.1.6 Gender-Specific Epidemiology
  • 8.1.7 Forecast Analysis (2025-2045)
  • 8.1.8 Epidemiology Growth Drivers
  • 8.1.9 Growth Opportunities
• 8.2 Europe
  • 8.2.1 Total Prevalence
  • 8.2.2 Total Incidence
  • 8.2.3 Diagnosed Cases
  • 8.2.4 Disease Type Distribution
  • 8.2.5 Age-Specific Epidemiology
  • 8.2.6 Gender-Specific Epidemiology
  • 8.2.7 Forecast Analysis (2025-2045)
  • 8.2.8 Epidemiology Growth Drivers
  • 8.2.9 Growth Opportunities
• 8.3 Asia-Pacific
  • 8.3.1 Total Prevalence
  • 8.3.2 Total Incidence
  • 8.3.3 Diagnosed Cases
  • 8.3.4 Disease Type Distribution
  • 8.3.5 Age-Specific Epidemiology
  • 8.3.6 Gender-Specific Epidemiology
  • 8.3.7 Forecast Analysis (2025-2045)
  • 8.3.8 Epidemiology Growth Drivers
  • 8.3.9 Growth Opportunities
• 8.4 Latin America
  • 8.4.1 Total Prevalence
  • 8.4.2 Total Incidence
  • 8.4.3 Diagnosed Cases
  • 8.4.4 Disease Type Distribution
  • 8.4.5 Age-Specific Epidemiology
  • 8.4.6 Gender-Specific Epidemiology
  • 8.4.7 Forecast Analysis (2025-2045)
  • 8.4.8 Epidemiology Growth Drivers
  • 8.4.9 Growth Opportunities
• 8.5 Middle East & Africa
  • 8.5.1 Total Prevalence
  • 8.5.2 Total Incidence
  • 8.5.3 Diagnosed Cases
  • 8.5.4 Disease Type Distribution
  • 8.5.5 Age-Specific Epidemiology
  • 8.5.6 Gender-Specific Epidemiology
  • 8.5.7 Forecast Analysis (2025-2045)
  • 8.5.8 Epidemiology Growth Drivers
  • 8.5.9 Growth Opportunities

9. Key Countries Analysis

• 9.1 United States
  • 9.1.1 Total Prevalence
  • 9.1.2 Total Incidence
  • 9.1.3 Diagnosed Cases
  • 9.1.4 Disease Type Distribution
  • 9.1.5 Age-Specific Epidemiology
  • 9.1.6 Gender-Specific Epidemiology
  • 9.1.7 Disease Severity Distribution
  • 9.1.8 Forecast Analysis (2025-2045)
• 9.2 Canada
  • 9.2.1 Total Prevalence
  • 9.2.2 Total Incidence
  • 9.2.3 Diagnosed Cases
  • 9.2.4 Disease Type Distribution
  • 9.2.5 Age-Specific Epidemiology
  • 9.2.6 Gender-Specific Epidemiology
  • 9.2.7 Disease Severity Distribution
  • 9.2.8 Forecast Analysis (2025-2045)
• 9.3 Germany
  • 9.3.1 Total Prevalence
  • 9.3.2 Total Incidence
  • 9.3.3 Diagnosed Cases
  • 9.3.4 Disease Type Distribution
  • 9.3.5 Age-Specific Epidemiology
  • 9.3.6 Gender-Specific Epidemiology
  • 9.3.7 Disease Severity Distribution
  • 9.3.8 Forecast Analysis (2025-2045)
• 9.4 United Kingdom
  • 9.4.1 Total Prevalence
  • 9.4.2 Total Incidence
  • 9.4.3 Diagnosed Cases
  • 9.4.4 Disease Type Distribution
  • 9.4.5 Age-Specific Epidemiology
  • 9.4.6 Gender-Specific Epidemiology
  • 9.4.7 Disease Severity Distribution
  • 9.4.8 Forecast Analysis (2025-2045)
• 9.5 France
  • 9.5.1 Total Prevalence
  • 9.5.2 Total Incidence
  • 9.5.3 Diagnosed Cases
  • 9.5.4 Disease Type Distribution
  • 9.5.5 Age-Specific Epidemiology
  • 9.5.6 Gender-Specific Epidemiology
  • 9.5.7 Disease Severity Distribution
  • 9.5.8 Forecast Analysis (2025-2045)
• 9.6 Italy
  • 9.6.1 Total Prevalence
  • 9.6.2 Total Incidence
  • 9.6.3 Diagnosed Cases
  • 9.6.4 Disease Type Distribution
  • 9.6.5 Age-Specific Epidemiology
  • 9.6.6 Gender-Specific Epidemiology
  • 9.6.7 Disease Severity Distribution
  • 9.6.8 Forecast Analysis (2025-2045)
• 9.7 Spain
  • 9.7.1 Total Prevalence
  • 9.7.2 Total Incidence
  • 9.7.3 Diagnosed Cases
  • 9.7.4 Disease Type Distribution
  • 9.7.5 Age-Specific Epidemiology
  • 9.7.6 Gender-Specific Epidemiology
  • 9.7.7 Disease Severity Distribution
  • 9.7.8 Forecast Analysis (2025-2045)
• 9.8 China
  • 9.8.1 Total Prevalence
  • 9.8.2 Total Incidence
  • 9.8.3 Diagnosed Cases
  • 9.8.4 Disease Type Distribution
  • 9.8.5 Age-Specific Epidemiology
  • 9.8.6 Gender-Specific Epidemiology
  • 9.8.7 Disease Severity Distribution
  • 9.8.8 Forecast Analysis (2025-2045)
• 9.9 Japan
  • 9.9.1 Total Prevalence
  • 9.9.2 Total Incidence
  • 9.9.3 Diagnosed Cases
  • 9.9.4 Disease Type Distribution
  • 9.9.5 Age-Specific Epidemiology
  • 9.9.6 Gender-Specific Epidemiology
  • 9.9.7 Disease Severity Distribution
  • 9.9.8 Forecast Analysis (2025-2045)
• 9.10 India
  • 9.10.1 Total Prevalence
  • 9.10.2 Total Incidence
  • 9.10.3 Diagnosed Cases
  • 9.10.4 Disease Type Distribution
  • 9.10.5 Age-Specific Epidemiology
  • 9.10.6 Gender-Specific Epidemiology
  • 9.10.7 Disease Severity Distribution
  • 9.10.8 Forecast Analysis (2025-2045)
• 9.11 South Korea
  • 9.11.1 Total Prevalence
  • 9.11.2 Total Incidence
  • 9.11.3 Diagnosed Cases
  • 9.11.4 Disease Type Distribution
  • 9.11.5 Age-Specific Epidemiology
  • 9.11.6 Gender-Specific Epidemiology
  • 9.11.7 Disease Severity Distribution
  • 9.11.8 Forecast Analysis (2025-2045)
• 9.12 Australia
  • 9.12.1 Total Prevalence
  • 9.12.2 Total Incidence
  • 9.12.3 Diagnosed Cases
  • 9.12.4 Disease Type Distribution
  • 9.12.5 Age-Specific Epidemiology
  • 9.12.6 Gender-Specific Epidemiology
  • 9.12.7 Disease Severity Distribution
  • 9.12.8 Forecast Analysis (2025-2045)

10. Competitive Landscape

• 10.1 Epidemiology Intelligence Providers
• 10.2 Real-World Data Providers
• 10.3 Disease Registry Landscape
• 10.4 Academic Research Organizations
• 10.5 Epidemiology Database Benchmarking
• 10.6 Competitive Positioning Analysis
• 10.7 Future Intelligence Trends

11. Company Profiles

• 11.1 IQVIA Holdings Inc.
  • 11.1.1 Overview
  • 11.1.2 Financials
  • 11.1.3 Epidemiology and Real-World Evidence Capabilities
  • 11.1.4 Neurology Research Portfolio
  • 11.1.5 Disease Registry Expertise
  • 11.1.6 Data Analytics Capabilities
  • 11.1.7 Strategic Collaborations
  • 11.1.8 Recent Developments
• 11.2 Clarivate Plc
  • 11.2.1 Overview
  • 11.2.2 Financials
  • 11.2.3 Epidemiology Intelligence Solutions
  • 11.2.4 Rare Disease Research Capabilities
  • 11.2.5 Data Analytics Capabilities
  • 11.2.6 Strategic Collaborations
  • 11.2.7 Recent Developments
• 11.3 Oracle Health Sciences
  • 11.3.1 Overview
  • 11.3.2 Financials
  • 11.3.3 Clinical Data and Epidemiology Solutions
  • 11.3.4 Real-World Evidence Capabilities
  • 11.3.5 Data Management Platforms
  • 11.3.6 Strategic Collaborations
  • 11.3.7 Recent Developments
• 11.4 ICON plc
  • 11.4.1 Overview
  • 11.4.2 Financials
  • 11.4.3 Epidemiology Research Capabilities
  • 11.4.4 Rare Disease Expertise
  • 11.4.5 Data Analytics Services
  • 11.4.6 Strategic Collaborations
  • 11.4.7 Recent Developments
• 11.5 Syneos Health, Inc.
  • 11.5.1 Overview
  • 11.5.2 Financials
  • 11.5.3 Epidemiology and RWE Capabilities
  • 11.5.4 Neurology Research Expertise
  • 11.5.5 Strategic Collaborations
  • 11.5.6 Recent Developments

12. Future Outlook and Opportunity Assessment

• 12.1 Future Epidemiology Trends
• 12.2 Diagnostic Improvement Impact
• 12.3 Disease Awareness Impact
• 12.4 Emerging Markets Opportunity Assessment
• 12.5 Research and Registry Expansion Trends
• 12.6 Strategic Recommendations
• 12.7 Long-Term Forecast Outlook (2025-2045)

13. Research Methodology

• 13.1 Primary Research
• 13.2 Secondary Research
• 13.3 Epidemiology Modelling Methodology
• 13.4 Forecasting Methodology
• 13.5 Data Validation and Triangulation
• 13.6 Assumptions and Limitations

14. Appendix

• 14.1 Abbreviations
• 14.2 Glossary of Terms
• 14.3 References
• 14.4 List of Tables
• 14.5 List of Figures
• 14.6 Epidemiology Data Sources
• 14.7 Country-Level Data Sources
• 14.8 Public Health and Registry Sources